Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Rupert Bauersachs"'
Autor:
Rupert Bauersachs
Publikováno v:
DMW - Deutsche Medizinische Wochenschrift. 146:1237-1242
EPIDEMIOLOGY AND RISK FACTORS: A large German registry on superficial vein thrombosis (SVT) documents that risk profiles, clinical presentation and treatment patterns are highly variable in patients with SVT, including a large variation in anticoagul
Publikováno v:
Journal of Vascular Surgery: Venous and Lymphatic Disorders. 9:1597-1598
Autor:
Ulrich Hoffmann, Rupert Bauersachs, Thomas Noppeney, Jens Klotsche, Horst E. Gerlach, Andreas Heinken, Eberhard Rabe, Florian Länger, David Pittrow
Publikováno v:
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery. 62(2)
Objective Management and outcomes of superficial vein thrombosis (SVT) are highly variable and not well described. Therefore, the INvestigating SIGnificant Health TrendS in the management of SVT (INSIGHTS-SVT) study collected prospective data under r
Autor:
Rupert Bauersachs, Jan Beyer-Westendorf, Sebastian Schellong, Katja Jersemann, Kurtulus Sahin, Horst E. Gerlach, Jeffrey I. Weitz, Eberhard Rabe
Publikováno v:
The Lancet Haematology. 4:e105-e113
Summary Background Superficial-vein thrombosis can lead to deep-vein thrombosis and pulmonary embolism. Rivaroxaban, an oral factor Xa inhibitor, might simplify treatment compared with fondaparinux because it does not require daily subcutaneous injec
Autor:
Horst E. Gerlach, Eberhard Rabe, Sebastian Schellong, Jan Beyer-Westendorf, Sebastian Werth, Rupert Bauersachs
Publikováno v:
Journal of Thrombosis and Thrombolysis. 42:197-204
Patients with superficial vein thrombosis (SVT) are commonly treated with low-molecular weight heparin or fondaparinux in prophylactic, intermediate or therapeutic dosages for treatment periods of 10-45 days. This practice is also reflected by the cu
Autor:
Rupert Bauersachs, Horst Eberhard Gerlach, Andreas Heinken, Ulrich Hoffmann, Florian Langer, Thomas Noppeney, David Pittrow, Jens Klotsche, Eberhard Rabe, Christian Schnabl, Tina Winterbauer, Norbert Schön, Harriet Simone Werno, Georg Herman, Oliver Schmidt, Beate Dietrich, Martin Schünemann, Eberhard Rieker, Ulrich Ruppe, Gabriele Betzl, Peter Heilberger, Dimitrios Tsantilas, Andreas Köpp, Lutz Forkmann, Andreas Willeke, Gabriele Rothenbücher, Karl Förster, Jeanette Kießling, Gesche Junge, Ina Wittig, Dagmar Wilms, Christoph Schulte, Stephan Flüchter, Martina Kneist, Ulrike Kirsch, Thomas Herrmann, Alexandra Turowski, Karsten Hartmann, Wolfram Oettler, Heike Nelles, Jürgen Frank, Savvas Apostolidis, Dag-Alexander Keilhau, Renate Murena Schmidt, Iris Rocha Rivera-Reuver, Kerstin Augustin, Diethard Predel, Thomas Hertel, Ursula Schmeink, Simone Seibt, Jürgen Schreiner, Christine Zollmann, Eckart Möbius, Thomas Vollmer, Roswitha Brettschneider, Sabine Raulin, Siamak Pourhassan, Gerlind Läger, Robert Brandl, Rainer Schmiedel, Karoline Jager, Erika Mendoza, Jörg Schwuchow, Jan-Peter Siegers, Peter Gätzschmann, Dimitrios Zgouras, Werner Lang, Arne Clasing, Anatoli Ananin, Jörg Rutkowski, Christoph Kalka, Frank Ackermann, Stephan Guggenbichler, Fred Peter, Patricia Schaub, Jan Beyer-Westendorf, Bernadette Brado, Mario Schöniger, Sven Köpnick, Ferenc Biro, Birgit Linnemann
Publikováno v:
Journal of vascular surgery. Venous and lymphatic disorders. 5(4)
Objective Superficial vein thrombosis (SVT) is a common disease in clinical practice. In terms of pathophysiology and outcomes, the condition is related to venous thromboembolism, bearing a potential for severe thromboembolic complications if it is n
Autor:
Horst E. Gerlach, Rupert Bauersachs, Eberhard Rabe, Jeffrey I. Weitz, Kurtulus Sahin, Jan Beyer-Westendorf, Katja Jersemann, Sebastian Schellong
Publikováno v:
The Lancet Haematology. 4:e254-e255
Rivaroxaban Versus Fondaparinux in the Treatment of Superficial Vein Thrombosis - the Surprise Trial
Autor:
Sebastian Schellong, Jan Beyer-Westendorf, Horst E. Gerlach, Eberhard Rabe, Rupert Bauersachs, Katja Jersemann, Kurtulus Sahin
Publikováno v:
Blood. 128:85-85
Background The current standard of therapy in superficial vein thrombosis (SVT) comprises subcutaneous injections of the indirect factorXainhibitorfondaparinuxfor up to 45 days, which was highlyeffectivecompared to placebo in the CALISTO trial. Howev